2,5-Dichloropyrimidine → rac-trans-(2-(((5-Chloropyrimidin-2-yl)amino)methyl)-3-methylpiperidin-1-yl)(5-(4-fluorophenyl)-2-methylthiazol-4-yl)methanone
반응식
Cl[C:2]1[N:7]=[CH:6][C:5]([Cl:8])=[CH:4][N:3]=1.[NH2:9][CH2:10][C@H:11]1[C@H:16]([CH3:17])[CH2:15][CH2:14][CH2:13][N:12]1[C:18]([C:20]1[N:21]=[C:22]([CH3:32])[S:23][C:24]=1[C:25]1[CH:30]=[CH:29][C:28]([F:31])=[CH:27][CH:26]=1)=[O:19]>>[Cl:8][C:5]1[CH:4]=[N:3][C:2]([NH:9][CH2:10][C@H:11]2[C@H:16]([CH3:17])[CH2:15][CH2:14][CH2:13][N:12]2[C:18]([C:20]2[N:21]=[C:22]([CH3:32])[S:23][C:24]=2[C:25]2[CH:26]=[CH:27][C:28]([F:31])=[CH:29][CH:30]=2)=[O:19])=[N:7][CH:6]=1참가 물질
3
실험 절차
The title compound was prepared following the same general protocol as described for Example 16 using 2,5-dichloropyrimidine and rac-trans-(2-(aminomethyl)-3-methylpiperidin-1-yl)(5-(4-fluorophenyl)-2-methylthiazol-4-yl)methanone. MS (ESI) 460.4 (M+H).
출처 및 근거
- ORD 기록
- ord-6082887debae4031800af1ee49d6c407